• / Free eNewsletters & Magazine
  • / My Account
Home>Enanta Pharmaceuticals Announces Preliminary Data from AbbVie’s Phase 3b RUBY-I Study in Chronic Hepatitis C Patients with Renal Impairment Presented at The International Liver Congress™ 2015

Enanta Pharmaceuticals Announces Preliminary Data from AbbVie’s Phase 3b RUBY-I Study in Chronic Hepatitis C Patients with Renal Impairment Presented at The International Liver Congress™ 2015

3party Content

Sat, 25 Apr 2015

Enanta Pharmaceuticals Announces Preliminary Data from AbbVie’s Phase 3b RUBY-I Study in Chronic Hepatitis C Patients with Renal Impairment Presented at The International Liver Congress™ 2015
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.